Michigan Medicine has partnered with Jansen to launch the second COVID-19 vaccine trial spearheaded by the University of Michigan hospital system.
U-M, one of many testing centers in connection with the U.S. Department of Health and Human Services’ coronavirus vaccine development effort Operation Warp Speed, is looking to round up volunteers as soon as possible.
The double-blind Phase 3 trial, named ENSEMBLE, will help researchers determine the effectiveness of a COVID-19 vaccine meant to eliminate the spread of the virus.
“Michigan Medicine is committed to supporting the continued study of the investigational Janssen vaccine and other vaccine candidates,” said Marschall Runge, dean of UM Medical School and CEO for Michigan Medicine. “These trials are crucial to moving us toward an effective vaccine.”
The trial will consist of 60,000 diverse participants from around the world. Volunteers must be 18+ to take part in the trial and can find more information HERE.
In September, U-M joined forces with AstraZeneca to begin AZD1222, a Phase 3 clinical trial testing a different COVID-19 vaccine on 30,000 volunteers. The study is set to end in 2022.
About Post Author
